DGTR initiates anti-dumping investigation on 6-APA from China and the European Union
The Directorate General of Trade Remedies has initiated an anti-dumping investigation concerning imports of 6-Amino Penicillanic Acid (6-APA) originating in or exported from China and the European Union. The initiation notification is dated September 25, 2026 (SETU Case ID AD/OI/059/2026).
The Directorate General of Trade Remedies has initiated an anti-dumping investigation concerning imports of 6-Amino Penicillanic Acid (6-APA) originating in or exported from China and the European Union. The initiation notification is dated September 25, 2026 (SETU Case ID AD/OI/059/2026).
The application was filed by Qule Pharma Private Limited, which states that it is the only producer of 6-APA in India, that earlier Indian production had shut down, and that it began producing in FY 2024-25. Its related entities Apitoria Pharma Private Limited and Aurobindo Pharma Limited imported the product for downstream manufacture; the Authority considers that this does not change the applicant's status as a manufacturer.
6-APA is a derivative of Penicillin-G used to make beta-lactam antibiotics such as Amoxycillin and Ampicillin. It is classifiable under heading 2941 10 50, which is indicative only. The period of investigation is April 1, 2025 to March 31, 2026, and the injury period covers 2022-23, 2023-24, 2024-25 and the period of investigation.
The case is framed as material retardation to the establishment of a domestic industry. On the applicant's evidence, the Authority finds prima facie a positive dumping margin above the de minimis level, notes that the two subject sources supply virtually all imports, and finds sufficient evidence of material retardation and a causal link. The applicant's request for preliminary findings and provisional duty will be considered at the appropriate stage.
Interested parties are to file submissions on the SETU portal within 37 days from transmission of the intimation letters.
- Measure
- Anti-dumping
- Stage
- Initiation
- Case number
- SETU CASE ID - AD/OI/059/2026
- File number
- F. No. 6/58/2026-DGTR
- Dated
- September 25, 2026
- Published in the Gazette
- September 25, 2026
- Put online
- October 3, 2026
- Gazette ID
- CG-DL-E-03102026-276770
- Product
- 6-Amino Penicillanic Acid (6-APA)
- What it covers
- 6-APA is an organic chemical compound and a direct derivative of Penicillin-G, used as a drug intermediate in the synthesis of beta-lactam antibiotics, principally Amoxycillin, Ampicillin, Cloxacillin, Dicloxacillin, Flucloxacillin and Oxacillin, and in medicinal chemistry, enzyme engineering, industrial biotechnology and antibiotic research.
- Customs codes
- 2941 10 50
- Countries
- China, European Union
- Applicant
- Qule Pharma Private Limited
- Period of investigation
- 1st April 2025 to 31st March 2026 (12 months)
- Injury period
- Financial years 2022-23, 2023-24, 2024-25 and the period of investigation
- Findings
- The applicant claims to be the sole producer of 6-APA in India and to account for 100% of domestic production; it states that earlier Indian production of 6-APA had shut down and that it commenced production in FY 2024-25.
- The applicant has not imported the product, but its related entity Apitoria Pharma Private Limited and its holding company Aurobindo Pharma Limited imported it for downstream manufacture; the Authority considers that these imports, consumed and not resold, do not change the applicant's nature as a manufacturer, and treats it as the domestic industry.
- For initiation, normal value for both China and the European Union was based on the domestic industry's cost of production with a reasonable addition for selling, general and administrative expenses and profit; export price was based on the CIF price in DG Systems transaction-wise import data.
- The comparison at ex-factory level prima facie shows a positive dumping margin above the de minimis level for imports from the subject countries.
- The applicant claims material retardation to the establishment of the domestic industry: production and sales below its expected performance, capacity utilization low in relation to demand in India, imports entering below its cost of sales, forced price reductions, and losses, cash losses and negative returns in the POI.
- The Authority notes that the subject countries account for virtually the entire imports of the product into India in the period of investigation, and finds sufficient prima facie evidence of material retardation and a causal link.
- Recommendation
- The Authority initiates an anti-dumping investigation under Section 9A of the Act read with Rule 5 of the AD Rules, 1995 to determine the existence, degree and effect of the alleged dumping and to recommend the duty adequate to remove injury. The applicant's request for preliminary findings and provisional anti-dumping duty under Rule 13 is to be considered, if and to the extent warranted, at the appropriate stage.
- Time limits
- Interested parties to upload submissions and questionnaire responses (confidential and non-confidential versions) on the SETU portal, including comments on the request for provisional duty: within 37 days from the date of transmission of the intimation letters, containing the non-confidential version of the application and the questionnaire(s), to the known interested parties and the diplomatic representative(s) of the subject country/countries
- Comments on the scope of the PUC and the proposed PCN methodology: within 15 days from the date of transmission of the intimation letters, running concurrently with the main time limit
- Requests for extension of time: at least one day before the original deadline
- Comments on issues of confidentiality: within 7 days from the date of circulation of the non-confidential version of the documents
The notification (PDF, 964 KB)
Gazette of India, CG-DL-E-03102026-276770, published September 25, 2026.
Checked against the official copy on October 20, 2026.